Recent hypertension trials: implications and controversies.
about
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of strokePrevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR StudyChoice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysisTrust in physicians and blood pressure control in blacks and whites being treated for hypertension in the REGARDS studyOlmesartan medoxomil for the treatment of hypertension in children and adolescentsReducing personal exposure to particulate air pollution improves cardiovascular health in patients with coronary heart disease.JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Managing hypertension in general practice: a cross-sectional study of treatment and ethnicityTargeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Class effects and labeling of antihypertensive drugs.Therapeutic potential of angiotensin receptor blockers in hypertension.Optimizing hypertension management in clinical practice.Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.A "patient-tailored" treatment of hypertension with use of impedance cardiography: a randomized, prospective and controlled trialAntihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.New and emerging risk factors for CVD.Amlodipine and valsartan as components of a rational and effective fixed-dose combination.The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension.Protective effects of renin-angiotensin blockade beyond blood pressure control.Hypertension, the changing pattern of drug usage.What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review.Prevalence, self-awareness, treatment, and control of hypertension in Lhasa, Tibet.The prevalence, predictors and associations of hypertension in Sri Lanka: a cross-sectional population based national survey.Use of predictive markers to improve cardiovascular protection.Profiles of mortality among Chinese hypertensive patients in Hong Kong: a cohort study.Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study.Treatment of hypertension in rural Cambodia: results from a 6-year programme.Who benefits more from hemodynamically guided hypotensive therapy? The experience from two randomized, prospective and controlled trials.
P2860
Q28219593-3748F3C7-5241-486C-BDEB-93127B822EF5Q34218945-D5FBCE1A-0199-4F9F-BB5E-CDFEA059F066Q34219946-8B169A2F-A840-4EA1-B30D-83AD2D1AAF54Q34629543-9181A5CA-E9CA-4D18-8F86-87992168C476Q34772915-9EA34D38-726D-4933-9AA9-61E71D8C3597Q35807843-39169057-E4B7-40B4-93A2-54060E3358E5Q35808362-E2C6147C-1F3F-4F69-888F-90CC8F57F574Q36284269-FDC42097-6938-4F8E-AF2C-A2CB22A471AFQ36302833-FD1EE468-B6CB-4045-A991-1A16FB67C628Q36416119-9E69660B-AD86-4AEB-8D1F-AABD521DCA99Q36491825-2DE803C0-0917-4C7E-B8E9-24D0F76B9C3CQ36568468-358CD96F-C298-486E-9E5B-85130AEA48D3Q36766964-C1B931C7-E79B-4929-B057-C1CA86C9CAC3Q36859492-C0C1B1A3-09A0-4D5A-B1C0-4ECFD6B358ACQ36867310-56051C9B-737A-4427-83FF-D738AA44723AQ37135582-ABC46E31-E62D-4AF6-8D90-587EF64ACADAQ37138669-0493AE0D-42CE-4F8A-BC38-F2EBF57D5D17Q37167534-3A88D327-A356-4437-BE9D-026109926952Q37362695-FBDA8956-DAFA-4DC0-BACF-48C918085995Q37384710-4A602517-80C6-41BE-84BB-65639AD639ECQ37415325-734C1A03-D06E-452D-A537-E073C0159543Q37925640-E56E1DB6-3A31-471D-BDED-08CC7E2DD58BQ38971285-9BDB504A-3F9C-41A4-82A1-50C7A6047EBDQ40028744-4CADF769-9EB4-41F7-BAB9-2E9CD8E95DB8Q40164398-2520E2A2-D06F-457D-A155-0D4C3AFED308Q40199205-E97188DD-FF96-40F6-8B14-EAB12CB75452Q44821589-50C0A586-B4B6-44CA-9CB3-B0C9359BF458Q46668164-1C60B9D6-8E9B-4ED3-9A5D-D5CB092440CFQ51374119-853B6F05-66A3-48C6-B731-2164D300072FQ51567367-D3038223-7DD3-4A20-95E5-7AECA304AC84Q53652068-8F9008EA-6AB6-4E05-BD8C-BA977FB571E4
P2860
Recent hypertension trials: implications and controversies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Recent hypertension trials: implications and controversies.
@ast
Recent hypertension trials: implications and controversies.
@en
type
label
Recent hypertension trials: implications and controversies.
@ast
Recent hypertension trials: implications and controversies.
@en
prefLabel
Recent hypertension trials: implications and controversies.
@ast
Recent hypertension trials: implications and controversies.
@en
P1476
Recent hypertension trials: implications and controversies.
@en
P2093
Bryan Williams
P304
P356
10.1016/J.JACC.2004.10.069
P407
P577
2005-03-01T00:00:00Z